Tuesday, November 08, 2022 9:40:48 PM
I would not be surprised if your friend's model, that there are 1.2B naked shorted shares of NWBO, is true. It is speculation for me at this point, but that extent of manipulation would not surprise me. Why? Because the stock price is so far unnaturally removed from the underlying value of the DCVax platform. IMHO, NWBO today, prior to regulatory approval, the value is at least 5X to 10X higher than the stock price. After RA approval, the value should further do a step value increase.
That equals a short position of $880M today (1.2B shares X $0.7385 price), not sure if that is a large short position for major hedge funds but the exposure to loss for sure is astronomical. And the years pushing down price and against an expanding investor base relying on published successful Phase 3 clinical trial results, that requires lots of shorting activity. So I would not be surprised at all of the required scale of shares shorted to keep price down.
Consequentially, I would not be surprised of a corresponding mega, short squeeze scenario either.
That equals a short position of $880M today (1.2B shares X $0.7385 price), not sure if that is a large short position for major hedge funds but the exposure to loss for sure is astronomical. And the years pushing down price and against an expanding investor base relying on published successful Phase 3 clinical trial results, that requires lots of shorting activity. So I would not be surprised at all of the required scale of shares shorted to keep price down.
Consequentially, I would not be surprised of a corresponding mega, short squeeze scenario either.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
